These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26271588)

  • 1. Recent progress in the development of small-molecule glucagon receptor antagonists.
    Sammons MF; Lee EC
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4057-64. PubMed ID: 26271588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of potent and orally bioavailable indazole-based glucagon receptor antagonists for the treatment of type 2 diabetes.
    Xu G; Gaul MD; Song F; Du F; Liang Y; DesJarlais RL; DiLoreto K; Shook B; Rentzeperis D; Santulli R; Eckardt A; Demarest K
    Bioorg Med Chem Lett; 2019 Oct; 29(20):126668. PubMed ID: 31519374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A survey of small molecule glucagon receptor antagonists from recent patents (2006 - 2010).
    Shen DM; Lin S; Parmee ER
    Expert Opin Ther Pat; 2011 Aug; 21(8):1211-40. PubMed ID: 21635155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Landmark studies on the glucagon subfamily of GPCRs: from small molecule modulators to a crystal structure.
    Yang DH; Zhou CH; Liu Q; Wang MW
    Acta Pharmacol Sin; 2015 Sep; 36(9):1033-42. PubMed ID: 26279155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus.
    Guzman-Perez A; Pfefferkorn JA; Lee EC; Stevens BD; Aspnes GE; Bian J; Didiuk MT; Filipski KJ; Moore D; Perreault C; Sammons MF; Tu M; Brown J; Atkinson K; Litchfield J; Tan B; Samas B; Zavadoski WJ; Salatto CT; Treadway J
    Bioorg Med Chem Lett; 2013 May; 23(10):3051-8. PubMed ID: 23562063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes.
    Scheen AJ; Paquot N; Lefèbvre PJ
    Expert Opin Investig Drugs; 2017 Dec; 26(12):1373-1389. PubMed ID: 29052441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon as a target for the treatment of Type 2 diabetes.
    Sloop KW; Michael MD; Moyers JS
    Expert Opin Ther Targets; 2005 Jun; 9(3):593-600. PubMed ID: 15948676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic modeling of a monoclonal antibody antagonist of glucagon receptor in male ob/ob mice.
    Lau YY; Ma P; Gibiansky L; Komorowski R; Wang J; Wang G; Yan H; Véniant MM; Kakkar T
    AAPS J; 2009 Dec; 11(4):700-9. PubMed ID: 19851873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection and characterization of DNA aptamer against glucagon receptor by cell-SELEX.
    Wang G; Liu J; Chen K; Xu Y; Liu B; Liao J; Zhu L; Hu X; Li J; Pu Y; Zhong W; Fu T; Liu H; Tan W
    Sci Rep; 2017 Aug; 7(1):7179. PubMed ID: 28775305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists.
    Dallas-Yang Q; Shen X; Strowski M; Brady E; Saperstein R; Gibson RE; Szalkowski D; Qureshi SA; Candelore MR; Fenyk-Melody JE; Parmee ER; Zhang BB; Jiang G
    Eur J Pharmacol; 2004 Oct; 501(1-3):225-34. PubMed ID: 15464082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological targeting of glucagon and glucagon-like peptide 1 receptors has different effects on energy state and glucose homeostasis in diet-induced obese mice.
    Gu W; Lloyd DJ; Chinookswong N; Komorowski R; Sivits G; Graham M; Winters KA; Yan H; Boros LG; Lindberg RA; Véniant MM
    J Pharmacol Exp Ther; 2011 Jul; 338(1):70-81. PubMed ID: 21471191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of glucagon and insulin action reveals a role for the GLP-1 receptor in endogenous glucose production.
    Jun LS; Millican RL; Hawkins ED; Konkol DL; Showalter AD; Christe ME; Michael MD; Sloop KW
    Diabetes; 2015 Mar; 64(3):819-27. PubMed ID: 25288673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia.
    Gu W; Yan H; Winters KA; Komorowski R; Vonderfecht S; Atangan L; Sivits G; Hill D; Yang J; Bi V; Shen Y; Hu S; Boone T; Lindberg RA; Véniant MM
    J Pharmacol Exp Ther; 2009 Dec; 331(3):871-81. PubMed ID: 19720878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational identification of novel natural inhibitors of glucagon receptor for checking type II diabetes mellitus.
    Grover S; Dhanjal JK; Goyal S; Grover A; Sundar D
    BMC Bioinformatics; 2014; 15 Suppl 16(Suppl 16):S13. PubMed ID: 25521597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-diabetic efficacy and impact on amino acid metabolism of GRA1, a novel small-molecule glucagon receptor antagonist.
    Mu J; Qureshi SA; Brady EJ; Muise ES; Candelore MR; Jiang G; Li Z; Wu MS; Yang X; Dallas-Yang Q; Miller C; Xiong Y; Langdon RB; Parmee ER; Zhang BB
    PLoS One; 2012; 7(11):e49572. PubMed ID: 23185367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extra-helical binding site of a glucagon receptor antagonist.
    Jazayeri A; Doré AS; Lamb D; Krishnamurthy H; Southall SM; Baig AH; Bortolato A; Koglin M; Robertson NJ; Errey JC; Andrews SP; Teobald I; Brown AJ; Cooke RM; Weir M; Marshall FH
    Nature; 2016 May; 533(7602):274-7. PubMed ID: 27111510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and structure activity relationships of indazole and indole derivatives as potent glucagon receptor antagonists.
    Song F; Xu G; Gaul MD; Zhao B; Lu T; Zhang R; DesJarlais RL; DiLoreto K; Huebert N; Shook B; Rentzeperis D; Santulli R; Eckardt A; Demarest K
    Bioorg Med Chem Lett; 2019 Aug; 29(15):1974-1980. PubMed ID: 31138472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of RNA interference to improve mechanistic understanding of omics responses to a hepatotoxic drug in primary rat hepatocytes.
    Adler M; Leich E; Ellinger-Ziegelbauer H; Hewitt P; Dekant W; Rosenwald A; Mally A
    Toxicology; 2014 Dec; 326():86-95. PubMed ID: 25456269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).
    Filipski KJ
    Expert Opin Ther Pat; 2015 Jul; 25(7):819-30. PubMed ID: 25828189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.
    Sloop KW; Cao JX; Siesky AM; Zhang HY; Bodenmiller DM; Cox AL; Jacobs SJ; Moyers JS; Owens RA; Showalter AD; Brenner MB; Raap A; Gromada J; Berridge BR; Monteith DK; Porksen N; McKay RA; Monia BP; Bhanot S; Watts LM; Michael MD
    J Clin Invest; 2004 Jun; 113(11):1571-81. PubMed ID: 15173883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.